At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 510 enrolled
Drug / intervention
PureVision Contact Lens +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Product Performance of Bausch & Lomb PureVision® Contact Lens When Compared to Johnson & Johnson Acuvue Oasys Contact Lens and the Ciba Vision O2Optix Contact Lens Worn Daily.
In Brief
A Phase 4 clinical trial evaluating PureVision Contact Lens, Acuvue Oasys Contact Lens, and 1 other intervention for Myopia. Completed, enrolled 510 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the performance of the PureVision Contact Lens compared to Acuvue Oasys Contact lens and O2Optix Contact lens when worn on a daily wear basis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedMar 2008
Primary CompletionApr 2008
TodayJul 2026
First PostedMar 21, 2008
Enrollment StartFeb 1, 2008
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.3 years ago
Interventions
PureVision Contact Lensdevice
contact lens for daily wear
Acuvue Oasys Contact Lensdevice
contact lens for daily wear
O2Optix Contact lensdevice
contact lens for daily wear